These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24130766)

  • 21. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion.
    Kristinsson H; Smith DM; Bergsten P; Sargsyan E
    Endocrinology; 2013 Nov; 154(11):4078-88. PubMed ID: 24035997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1.
    Tunaru S; Bonnavion R; Brandenburger I; Preussner J; Thomas D; Scholich K; Offermanns S
    Nat Commun; 2018 Jan; 9(1):177. PubMed ID: 29330456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance.
    Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S
    Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus].
    Tsujihata Y
    Nihon Yakurigaku Zasshi; 2014 Aug; 144(2):59-63. PubMed ID: 25109517
    [No Abstract]   [Full Text] [Related]  

  • 27. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
    Araki T; Hirayama M; Hiroi S; Kaku K
    Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Characterization of a Promising Novel FFAR1/GPR40 Targeting Fluorescent Probe for β-Cell Imaging.
    Bertrand R; Wolf A; Ivashchenko Y; Löhn M; Schäfer M; Brönstrup M; Gotthardt M; Derdau V; Plettenburg O
    ACS Chem Biol; 2016 Jun; 11(6):1745-54. PubMed ID: 27115176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2016 Sep; 18(9):925-9. PubMed ID: 27178047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
    Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GPR40: a therapeutic target for mediating insulin secretion (review).
    Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
    Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans.
    Wagner R; Kaiser G; Gerst F; Christiansen E; Due-Hansen ME; Grundmann M; Machicao F; Peter A; Kostenis E; Ulven T; Fritsche A; Häring HU; Ullrich S
    Diabetes; 2013 Jun; 62(6):2106-11. PubMed ID: 23378609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1.
    Kohara K; Obata A; Kimura T; Shimoda M; Moriuchi S; Okauchi S; Hirukawa H; Mune T; Kaku K; Kaneto H
    Endocr J; 2019 Jan; 66(1):43-50. PubMed ID: 30333365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.
    Chen Y; Ren Q; Zhou Z; Deng L; Hu L; Zhang L; Li Z
    Br J Pharmacol; 2020 May; 177(10):2286-2302. PubMed ID: 31971610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
    Choi YJ; Shin D; Lee JY
    Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
    Marcinak J; Cao C; Lee D; Ye Z
    Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.